STADA Arzneimittel — Investor Presentation (July 2025)
103 slides from STADA Arzneimittel's investor presentation, July 2025
Slide 1: Caring for People's Health Company Presentation June-July 2025
Caring for People’s Health Company Presentation June-July 2025
Slide 2: Important Notice
Important Notice THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DIS
Slide 3: Important Notice
Important Notice The information contained in this Presentation is not to be viewed from nor for publication or distribution in nor taken or transmitted into the United States of America, its territories and possessions, any State of the United States, and the District of Columbia (“United States”),
Slide 4: Important Notice
Important Notice This Presentation includes certain consolidated financial information of Nidda German Topco GmbH and, in addition, includes certain financial measures that are not recognized by IFRS or any other generally accepted accounting principles, including measures based on or derived from c
Slide 5: Important Notice
Important Notice This Presentation, where indicated, includes information from different sources. The information derived from market research information provided by IQVIA and its affiliated companies (“IQVIA”) includes data from the following data offerings: IQVIA MIDAS®, IQVIA Consumer Health Cus
Slide 6: Important Notice
Important Notice "Sanofi Commercial Alliance": Involves the following brands that are presently listed in the data under Sanofi instead of STADA: (Bulgaria) Essentiale; (Estonia) Magne B6, Maalox, No Spa, Essentiale, Ipraalox, Finalgon, Dulcolax; (Finland) Bisolvon, Nasacort, Telfast, Laxoberon; (Fr
Slide 7: Introduction, Financial Highlights, STADA's Strategy, Appendix
Introduction 8 Financial Highlights 17 STADA’s Strategy 31 Appendix STADA’s Segments 55 Governance & ESG 87 Financials 92 Privileged and Confidential 7
Slide 8: STADA – A distinctive investment case in Healthcare
STADA – A distinctive investment case in Healthcare
Slide 9: A leading supplier of healthcare products across Self-Care, Primary Care and Specialty Care
A leading supplier of healthcare products across Self-Care (Consumer Healthcare), Primary Care (Generics) and Specialty Care (Specialty), fully integrated across global product development, procurement and manufacturing, and commercialization
Slide 10: STADA – A leading supplier of Healthcare products
Investment highlights Who We Are STADA – A leading supplier of Healthcare1 products Key financials 2024 Revenues by segment2 Revenues by product2,3,4 Revenues by country2,3,5 Consumer Uzpruvo® Kinpeygo® Specialty Corpos® €4.1bn Versatis® Healthcare Movymia® Nizoral® Rest of World6 Revenues (“Sx”) Hu
Slide 11: Since 2017, significant transformation of a ~130 year heritage company
Investment highlights Where we come from Since 2017, significant transformation of a ~130 year heritage company into a leading supplier of Healthcare1 products Revenues (€bn) Adj. EBITDA (€bn) 6 1.5 CAGR CAGR 1.3 +12% +17% 5 4.1 3.7 1.1 4 3.3 0.9 2.9 0.9 0.8 3 0.7 0.5 0.7 2 0.5 0.3 1 0.1 0 2017 2021
Slide 12: STADA's resilience based on diversification and manufacturing footprint
Investment highlights Diversified platform STADA's resilience based on diversification and manufacturing footprint Diversification of Segments and Broad Based Manufacturing Well-positioned regarding US Tariff Products Capacity to Ensure Supply Reliability Challenges 2024 Revenues by product1,2 Overv
Slide 13: Focused on large, growing and mostly non-cyclical European Healthcare markets
Investment highlights Markets Focused on large, growing and mostly non-cyclical European Healthcare markets Consumer Healthcare Market Generics Market Specialty Market European Consumer Healthcare market, EUR bn gross European Generics market, EUR bn gross sales European Specialty market, EUR bn gro
Slide 14: Consistently outperformed relevant European markets
Investment highlights Markets Consistently outperformed relevant European markets driven by strong organic growth Consumer Healthcare (38%1) Generics (41%1) Specialty (21%1) The fastest-growing major Consumer Health- A leading Generics player Attractive portfolio of Biosimilars, Specialty care compa
Slide 15: Three distinct strategies to differentiate STADA in each segment
Investment highlights Segments Three distinct strategies to differentiate STADA in each segment Consumer Healthcare Generics Specialty • Driving portfolio of Local Hero brands1 • Deliberate geographic footprint (e.g. no • Build and grow portfolio with complex, across OTC categories and STADA USA) wi
Slide 16: STADA – investment highlights summary
Focused on large, mostly non-cyclical markets growing mid 1 single to low double digit Track-record of outperforming relevant markets1 with leading 2 positioning and attractive risk profile Differentiated strategy for Consumer Healthcare, Generics and Specialty – 3 with symbiotic nature of the three
Slide 17: Financial Highlights
Financial Highlights
Slide 18: All three segments with strong top- and bottom-line growth
Financials Segments 4Y All three segments with strong top- and bottom-line growth over the years and strong profitability of ~25% in CHC, ~24% in Gx and ~33% in Sx Group Consumer Healthcare Generics Specialty +12%/+11% +16%/+13% +8%/+8% +16%/+16% Total / organic1 CAGR 3,735 4,059 1,489 1,537 1,652 8
Slide 19: Strong organic growth driven by volume and product launches
Financials Segments 4Y Strong organic growth driven by volume and product launches in all three segments, Consumer Healthcare with highest price increases and inorganic growth1 Consumer Healthcare Generics Specialty +16% +8% CAGR +16% 870 1,497 1,652 749 1,489 1,537 1,307 1,414 603 1,281 559 986 Rev
Slide 20: STADA Q1 2025: Continuing to outgrow in revenues and profit
Q1 2025 Update Summary STADA Q1 2025: Continuing to outgrow in revenues and profit Key highlights in Q1 2025: A record quarter for STADA 1 Growth of +4% in Revenues and +5% Adj. cc EBITDA1 growth2: Adj. cc EBITDA at all-time-high of €245m 2 High resilience with no impact in Q1 / no meaningful expect
Slide 21: STADA with continuous growth in Q1, on track for 2025
Q1 2025 Update Revenues STADA with continuous growth in Q1, on track for another strong year in 2025 – with high resilience in a turbulent external environment Adj. cc Revenues1,3 (€m) Adj. cc EBITDA2,3 (€m) Growth (%) Growth (%) +4% 1,081 +5% 245 • Resilient revenue growth surpassing high PY-base,
Slide 22: Consumer Healthcare: Topline overall flat due to declining seasonal sell-in
Q1 2025 Update Consumer Healthcare Consumer Healthcare: Topline overall flat due to declining seasonal sell-in, while non- seasonal products with MSD1 growth Adj. cc Revenues (€m)2 Growth (%) -0.7% • High PY-base in Q1 20244 - impacted by strong sell-in of 422 419 seasonal products (Cough & Cold / A
Slide 23: Generics: Strong growth outside of Germany
Q1 2025 Update Generics Generics: Strong growth outside of Germany based on continued launch successes Adj. cc Revenues (€m)1 Growth (%) +1% • Revenues up +1% against high PY-base which 418 423 included positive one-time-effects in Germany (supply phasing, rebate accrual release) Gx Germany +HSD% •
Slide 24: Specialty: Very strong growth based on biosimilars
Q1 2025 Update Specialty Specialty: Very strong growth based on biosimilars, esp. Ustekinumab, and innovative medicines Adj. cc Revenues (€m)1 Growth (%) • Strong revenue contribution of launches e.g. Ustekinumab, Nilotinib +22% 239 196 • Broad-based growth of in-market biosimilars esp. Oyavas (Beva
Slide 25: Q1 consistent growth, healthy P&L and record Adj. cc EBITDA
Q1 2025 Update STADA Group STADA in Q1 with consistent growth, healthy P&L-shape and a record quarterly Adj. cc EBITDA Q1 Revenues and Adj. cc EBITDA (€m) Q1'25 %-D vs PY Q1‘24 Revenue growth of +4%1 with: Revenues 1,081 +4% • Growth excl. seasonal products and one-time effects in PY - organic growt
Slide 26: On track for 2025 Guidance on Adj. cc EBITDA
Q1 2025 Update Guidance 2025 On track for 2025 Guidance on Adj. cc EBITDA despite softer C&C revenues, demonstrating resilience of STADA’s three segment model Guidance: € or growth rate percentage ranges 2024 Results: KPIs: 2025 Forecast Comment on range of outcome: Revenues €4,059m Adj. cc Revenues
Slide 27: Adj. cc EBITDA-evolution throughout the year
Q1 2025 Update Quarterly Progression Adj. cc EBITDA-evolution throughout the year: High H1 comparator in 2024 Adj. cc EBITDA H1 vs H2 – actual results 20241 Reminder: Half-yearly EBITDA-pattern 2024 52% 48% • H1 2024 unusually high based on strong seasonal sell-in and favorable one-time effects 457
Slide 28: Cash generative business model – Q1 cash conversion
Q1 2025 Update Cash conversion Cash generative business model – Q1 with M&A proceeds to fund growth investments Core Free Cash Flow1 (€m) FY’24 Q1’25 • Core Free Cash Flow exceeding average run-rate in Adj. cc EBITDA 100% 886 100% 245 FY 2024 (€197m vs. ~€142m) Taxes2 -129 -23 • Changes in NWC only
Slide 29: STADA's mid-term guidance
Q1 2025 Update Mid-term Guidance STADA’s mid-term guidance: Confident to deliver mid to high single digit topline and margin accretive bottom-line growth Guidance: € or growth rate percentage ranges 2025 Forecast 2024 Results KPIs: Mid-term Guidance (Q1-update) Revenues €4,059m Adj. cc Revenues1 ~€4
Slide 30: Capital allocation framework in case of a public market listing
Q1 2025 Update Capital allocation Capital allocation framework in case of a public market listing Organic growth investment Proactive management of maturities • Opex to support growth – under-proportionate to • Successful €1.3bn refinancing of Aug-2026 debt Revenues growth (operating leverage) matur
Slide 31: STADA's Strategy
STADA STADA’s Strategy
Slide 32: Our performance is based on a clear strategic framework
STADA’s Strategy Strategic Framework Our performance is based on a clear strategic framework with Growth Culture at its core Purpose “Caring for people’s health as a trusted partner” “To be the partner of choice in Consumer Health, Generics and Vision Specialty continuously outgrowing the industry i
Slide 33: Strong commercial focus on Europe and selected Emerging Markets
STADA’s Strategy Where to play STADA: Strong commercial focus on Europe and selected Emerging Markets Commercial focus: Europe (Revenues) Emerging Markets (Revenues) 2021 2024 2021 2024 Western Europe Eastern Europe Germany Source: Company information 33
Slide 34: All three segments have a highly complementary financial profile
STADA’s Strategy Summary All three segments have a highly complementary financial profile Consumer Healthcare Generics Specialty Continued financial Peak Revenues Peak Revenues 1 Product lifecycle investments in long in first year in 5 to 10 years term brand building Limited 2 Cyclicality cyclicalit
Slide 35: STADA realizes symbiotic effects across the segments
STADA’s Strategy Summary STADA realizes symbiotic effects across the segments and along the entire value chain Synergy area Consumer Healthcare Generics Specialty Commerciali- 1 zation/GTM Broad and symbiotic coverage (e.g. shared field force) API1 and packaging material procurement, Logistics 2 Pro
Slide 36: Strong momentum in 2025 along our five strategic priorities
STADA’s Strategy Strategic Priorities Strong momentum in 2025 along our five strategic priorities Strong Portfolio Low-cost operating Efficient and reliable Growth marketing and sales acceleration via model supply chain culture capabilities launches, BD&L and M&A • Successfully launched • Preparatio
Slide 37: Key Takeaways
STADA’s Strategy Summary Key Takeaways 1 STADA with its strong growth culture has a proven track record of outperforming its relevant markets organically across all three segments 2 Symbiotic business across Consumer Healthcare, Generics and Specialty with leading market positions in the attractive
Slide 38: Culture drives performance at STADA
STADA’s Strategy Growth Culture Culture drives performance at STADA 4 STADA - Acting in line with values 3"I amSTADA proud -toCaring work for forSTADA" employees 1 2 "I 2 amSTADA proud -toThe work for STADA" place to be NTM net sales growth (%) "I 1 amProud proud employees NTM net sales growth (%) t
Slide 39: Portfolio of Local Hero brands provides a flexible growth platform
STADA’s Strategy CHC – Local Hero brands STADA’s portfolio of Local Hero brands1 provides a flexible growth platform Number of Local Hero1 brands2 STADA’s Local Hero1 brands3 Europe and Eurasia By country 242 21 Other4 60 19 229 18 7 16 7 8 15 8 220 9 15 9 9 10 11 138 By category Cough & Cold 120 37
Slide 40: STADA is leading in market share gains in European market
STADA’s Strategy CHC – Market STADA is leading in terms of market share gains in European market 2019: 2023: 2024: STADA #10 in the market with 1.7% market share1 STADA #4 in the market with 2.9% market share1 STADA #4 in the market with 2.9% market share1 European market share by gross sales (2019)
Slide 41: STADA ranks #1 Innovation Freshness Index
STADA’s Strategy CHC – Innovations STADA is ranking #1 Innovation Freshness Index1, ahead of all key competitors2 Innovation Freshness Index1 Key Drivers % MAT Sales generated by last three years launches from the total MAT sales in March 2025 • Innovation pipeline is fueled by internal / external d
Slide 42: Accelerating growth via e-Commerce in profitable high growth markets
STADA’s Strategy CHC – e-Commerce Accelerating growth via e-Commerce in profitable high growth markets E-Com Revenues1 STADA's e-Com acceleration playbook 1 Focus e-Com efforts on countries with substantial e-Com size already and future growth potential 25% CAGR >10% of total Concentrate on e-Com su
Slide 43: E-commerce growth in Germany & China
STADA’s Strategy CHC – e-Commerce E-commerce growth in Germany & China: A growth engine for STADA Consumer Healthcare Germany eCommerce Revenues Development China eCommerce Revenues Development • e-Commerce revenues CAGR of +21%1 from 2021 • e-Commerce revenues CAGR of +79%1 from 2021 to 2024 to 202
Slide 44: STADA is outgrowing the top global CHC companies
STADA’s Strategy CHC – Market STADA is outgrowing the top 10 global CHC companies 2023: 2023: Top 10 global CHC players - Market share by value1 Top 10 global CHC players – Gross sales growth by value vs PY1 Haleon 5.9% 8.6% Kenue 4.1% 5.5% Sanofi 3.9% 4.9% Bayer 3.7% 3.7% P&G 2.6% 3.6% reckitt 2.4%
Slide 45: Transforming brands is a key growth driver for Consumer Healthcare
STADA’s Strategy CHC – Local Hero brands Transforming brands is a key growth driver for STADA Consumer Healthcare Selected brand highlights Doubled revenues since From disinfection concentrate to a From diarrhea medicine to acquisition through innovation successful household brand popular electrolyt
Slide 46: European market is more attractive than the US market
STADA’s Strategy Gx – Market The European market is a fundamentally more attractive market than the US market Characteristics of the EU & US Market Characteristics of the EU Generics market Characteristics of the US Generics market Market access & EMA >30 FDA regulatory Central regulatory authority
Slide 47: STADA has distinct strategic differentiators vs. competitor archetypes
STADA’s Strategy Gx – STADA Positioning STADA has distinct strategic differentiators vs. all competitor archetypes Strategic differentiators of STADA vs. competitor clusters Tailored business model Global Regional Local Indian • Strong commercial platform based on players champions champions players
Slide 48: Market opportunity set to expand on blockbuster LoEs
STADA’s Strategy Gx – Market STADA’s market opportunity is set to expand on the back of blockbuster LoEs Value of non-Specialty LoEs1 in Europe (originator gross sales, €bn) Highlights Forecasted 5.6 • Full visibility on LoE pipeline based on 5.3 originator drugs' patent protection 5.1 €4.6bn timeli
Slide 49: Strong track record of first-to-market launches
STADA’s Strategy Gx – Launch Performance STADA has a strong track record of first-to-market launches with potential for further growth with broad coverage of future LoEs STADA’s robust launch performance Strong coverage and launch capabilities Market value coverage for top 20 LoE launches in Europe
Slide 50: Specialty portfolio well balanced with high-growth and high stability
STADA’s Strategy Sx – Overview STADA Specialty portfolio is well balanced with high-growth and high stability STADA Specialty Revenues (including product category split for 2024) (€m) Description of product categories Higher Innovative 870 Drugs w/ market exclusivity addressing unmet clinical needs.
Slide 51: Movymia and Oyavas have taken significant market share
STADA’s Strategy Sx – Biosimilars Movymia® (Teriparatide) and Oyavas® (Bevacizumab) have taken significant market share showcasing the strength and breadth of STADA biosimilars Total European gross sales (€m) CAGR Total European gross sales (€bn) CAGR 2021 to 2024 2021 to 2024 253 212 194 203 201 22
Slide 52: Steady stream of high-value biologic LoEs on the horizon
STADA’s Strategy Sx – Biosimilars Steady stream of high-value biologic LoEs is on the horizon and STADA is well positioned as partner of choice for biosimilars Biosimilar LoE Pipeline Comments LoE value incl. STADA's coverage (€bn)1 22.3 • STADA proactively monitors upcoming Biologics LoEs and asses
Slide 53: STADA covers the majority of expanding specialty generics LoEs
STADA’s Strategy Sx – Specialty Generics STADA covers the majority of expanding specialty generics LoEs with strong partners Specialty Generics LoE Pipeline(1) Comments LoE value incl. STADA's coverage (€bn) • Strong track record of first-to-market launches based on development, BD&L, and regulatory
Slide 54: Strong deal funnel of Innovative Specialty in-licensing opportunities
STADA’s Strategy Sx – Innovative Specialty Strong deal funnel of Innovative Specialty in-licensing opportunities for the near future Deal funnel (n=185) Comments Number of products under evaluation split by therapeutic areas and stage of development Others Nephrology Neurology • Enhance the product
Slide 55: Appendix: Consumer Healthcare
Appendix Consumer Healthcare
Slide 56: Consumer Healthcare Overview
Consumer Healthcare Overview STADA – The fastest-growing Consumer Healthcare Business in Europe (2022-2024)1, driven by specific Go-To-Market approach 16% 13% #4 Other Revenues CAGR Organic Revenues in CHC Europe2 56% CAGR 2021-2024 5% 2021-2024 5% €1.5bn Spain 4% Revenues 2024 Kazakhstan 4% 5% Neth
Slide 57: Addressing the large, growing European Consumer Healthcare market
Consumer Healthcare Market Addressing the large, growing and resilient European Consumer Healthcare market European Consumer Healthcare market (€bn) Accelerating growth drivers CAGR +1.6% +4.6% +1.7% +2.1% +3.8% Increasing proportion of older people and population growth +6.2% 4 46 3 8 39 Increased
Slide 58: Delivering strong double digit growth across Europe
Consumer Healthcare Regions Delivering strong double digit growth across Europe STADA Consumer Healthcare Revenues (€bn) 2.5 Organic CAGR CAGR 21-241 +13% Others 18% Serbia 15% 2 CAGR +16% Poland 6% 1.5 1.5 1.5 France 21% 1.3 Belgium 10% 1 1.0 Kazakhstan 42% Spain 13% Italy 8% 0.5 Netherlands 30% UK
Slide 59: STADA's local operational focus is a competitive advantage
Consumer Healthcare Strategy & Value pillars STADA’s local operational focus is a competitive advantage STADA's strategy Typical industry strategy Local vs. HQ Local entrepreneurship vs Central headquarters driven with lean headquarters Brand type Local Hero brands vs Global brands Brand activation
Slide 60: Brand portfolio covers all main consumer health categories
Consumer Healthcare Portfolio STADA’s brand portfolio covers all main consumer health categories Cough & Cold Derma Pain & Relief Gastro VMS¹ Other CHC • Nasal decongestant • Anti-dandruff • Antivaricose • Laxatives • Mineral supplements • Sleeping remedies • Cough relief • Wound healing • Muscular
Slide 61: Strong commercial infrastructure across Europe, Eurasia and selected EM
Consumer Healthcare Marketing & Sales Capabilities STADA with strong commercial infrastructure covering almost all countries in Europe as well as Eurasia and selected EM1 covering est. ~100,000 pharmacies STADA covers >402 countries with ~2,300 internal sales force FTEs3 Significant sales power & pl
Slide 62: Nizoral: Reactivation of brand
Consumer Healthcare Local Hero brands Nizoral: Reactivation of brand by impactful activation and portfolio expansion Nizoral Revenues Key drivers CAGR 21-24 (%) 1 2019 – Launch of international campaign +24% 2 2023/24 – Line extensions: Daily range 3 2024 – Acquisition of Nizoral Cream in EMEA 2021
Slide 63: Zoflora: UK's #1 homecare disinfectant brand
Consumer Healthcare Local Hero brands Zoflora: UK’s #11 homecare disinfectant brand and Top 51 Cleaning brand in the UK Zoflora Revenues Key Launches CAGR 21-24 (%) 2021/22 Launch outside of disinfectant category 1 with activation via digital channels +7% 2 2023 Launch of floor and carpet cleaning p
Slide 64: Elotrans: From diarrhea to lifestyle
Consumer Healthcare Local Hero brands Elotrans: From diarrhea to lifestyle – a popular hydration and electrolyte solution Elotrans Revenues Key drivers CAGR 21-24 (%) 1979 – Launch of Elotrans - German STADA heritage brand 1 OTC solutions for treating dehydration resulting from diarrhea +62% 2 2023
Slide 65: Proven Local Hero playbook accelerates growth
Consumer Healthcare Local Hero brands STADA’s proven Local Hero playbook accelerates growth through localized strategies STADA's brand acceleration levers Select brand examples Brand (re)activation awake dormant equity to appeal to consumers and pharmacies Within a brand Brand strengthening to maxim
Slide 66: STADA is the #1 deal maker in Consumer Healthcare
Consumer Healthcare M&A STADA is the #1 deal maker in Consumer Healthcare1 and partner of choice for those looking to divest brands >200 brands acquired across all segments between 2018 and 2024 Critical M&A CHC Success Factors • Experienced integrator of brands into broader platform • Proven playbo
Slide 67: Opportunity to wake up a further >130 Sleeping Beauty brands
Consumer Healthcare Sleeping Beauty brands Prime opportunity to wake-up a further >130 Sleeping Beauty brands Selected Sleeping Beauty brands1,2 STADA’s Sleeping Beauty playbook Sleeping Beauties Cough Pain & & Cold Relief Gastro to be accelerated via proven playbook 1 Identify neglected brands with
Slide 68: Product development is a differentiator and growth driver
Consumer Healthcare Product launches Product development is a differentiator for STADA and a key driver of growth in Consumer Healthcare Revenue growth from launches Launches by category 2024 Pain Cough & Derma Gastro VMS Hygiene Other & Cold Relief Baltics, >4% Nordics, Netherlands, Slovakia, Slove
Slide 69: Digital capabilities drive high customer engagement
Consumer Healthcare Digital capabilities STADA's digital capabilities drive a high level of engagement with customers Digital medium Metric1 Description Example >500m impressions p.a. Company & brand webpages tailored Local Hero 531 to engage with consumers and enable Websites them to purchase on- o
Slide 70: Key Takeaways: Consumer Healthcare
Consumer Healthcare Summary Key Takeaways 1 STADA is the fastest-growing company among the top 10 global CHC players (2022- 2024)1, ranked #42 in the attractive €39bn European Consumer Healthcare market (2024) 2 Proven playbook with >240 Local Hero brands and the opportunity to wake up >130 Sleeping
Slide 71: Appendix: Generics
STADA Appendix Generics
Slide 72: Generics Overview
Generics Overview STADA – A leading Generics player in Europe and a growing business in Eurasia and Emerging Markets Spain 8% #4 ~85% 7% France organic player Europe, historic2 +targeted3 7% Revenues CAGR leading position Loss of Exclusivity Serbia 8% €XXXm (2021-2024) in key markets1 (LoE) coverage
Slide 73: Large, growing, complex European Generics market
Generics Market STADA addresses the large, growing, complex, fragmented and highly attractive European Generics market …requiring deep local skill and …and fragmented with competitive Large and growing market… localized GTM1 approach… landscape Gross sales by geography, €bn Illustrative indication o
Slide 74: Market growth expected to accelerate on LoE profit pool
Generics Market Market growth is expected to accelerate based on a large profit pool of LoEs European Generics market 2019-2028E, gross sales (€bn) 5.3% CAGR 5 34 4.7% CAGR 27 1 0 5 22 1 0 Further potential upside through increased Gx penetration and potential easing of price pressure 2019 Volume Pr
Slide 75: Well positioned to take advantage of increasing Generics penetration
Generics Market STADA is well positioned to take advantage from increasing Generics penetration Generics penetration by country Untapped off-patent market Bn std. units of Generics vs. total volume (incl. non-Generics) 2024 • Generics accounting for ~68%1 of vs. 2019 +7.9 +1.1 +1.6 +5.9 +1.6 +3.4 +6
Slide 76: STADA is the #4 Generics player in Europe
Generics STADA Positioning STADA is the #4 Generics player in Europe with a deliberate focus on retail Generics in attractive geographies Generics Revenues (€bn) Strong focus on Europe vs. 6% Gx market gross sales CAGR(2) • STADA is the #4(3) Generics player in Europe with 8 top-3 positions across E
Slide 77: Strong Generics platform with tailored GTM models
Generics STADA Positioning STADA with strong Generics platform across markets due to highly tailored GTM models and excellent local commercial execution Retail segment only Every market has local channel differences… …requiring a differentiated approach to GTM strategy Nordics Germany UK Excellent c
Slide 78: Broad INN portfolio covers all therapeutic areas
Generics STADA Positioning STADA’s broad and comprehensive INN portfolio covers all therapeutic areas1, with over 16k SKUs Nervous Alimentary Tract & Anti- Urology & Musculo-Skeletal Respiratory Cardiovascular System & Pain Metabolism Infectives Sex Hormones System System • Diabetes • Asthma Select
Slide 79: Key Takeaways: Generics
Generics Summary Key Takeaways STADA plays in the highly attractive European market: Large (€27bn generics gross 1 sales for 2024)1, accelerating in growth (~5% CAGR ‘24-’28E), with complex GTM framework and thus very profitable Leading positions in attractive and profitable markets (#4 player acros
Slide 80: Appendix: Specialty
STADA Appendix Specialty
Slide 81: Specialty Overview
Specialty Overview STADA Specialty – Successfully developing and commercialising high-value treatments and delivering double-digit growth Innovative 16% 6/6 ~300 customer-facing Revenues CAGR first-attempt Specialty Gx1 FTEs in 30 (2021-2024) EMA approvals (incl. Branded Gx) markets2 €XXXm €0.9bn €X
Slide 82: Broad expertise across therapeutic areas
Specialty Overview STADA Specialty has broad expertise across therapeutic areas and proven ability to build new capabilities Product category Innovative Biosimilars Specialty Gx (incl. branded Gx) • Neurology: Advanced Parkinson’s Disease, Multiple • Rheumatology: Rheumatoid Arthritis • Multiple Mye
Slide 83: Dedicated Specialty M&S platform
Specialty M&S Platform Dedicated Specialty M&S platform that is tailored to product/market needs and is ready to launch additional complex products Go-to-market channels for STADA’s Specialty portfolio1 STADA Specialty M&S Footprint4 Nordics WE2 EE3 Country >250 Sales Reps & Key Account Managers ~25
Slide 84: Lecigon and Kinpeygo launches
Specialty Innovative Specialty Lecigon and Kinpeygo demonstrate STADA’s ability to launch complex innovative therapies and establish new standards of care Lecigon® Kinpeygo® Launch partner & competitive edge Advanced Parkinson’s disease Immunoglobulin A nephropathy (IgAN) Acquisition from Lobsor Pha
Slide 85: Large funnel of opportunities for innovative therapies
Specialty Innovative Specialty STADA is evaluating a large funnel of opportunities for additional launch of innovative therapies STADA’s Innovative opportunity screening criteria Low develop- Attractive niche market Fit to portfolio ment risk Filter Close to launch Niche market/prescriber base, unat
Slide 86: Key Takeaways: Specialty
Specialty Summary Key Takeaways 1 Specialty is the fastest-growing and strongly profitable segment within STADA and includes the product categories Innovative, Biosimilars and Specialty Generics 2 STADA's Specialty platform at-scale is ready to take advantage of favorable secular trends to launch ma
Slide 87: Appendix: Governance & ESG
STADA Appendix Governance & ESG
Slide 88: Institutionalizing growth culture across the organization
Governance & ESG Growth Culture STADA is institutionalizing growth culture across the organization at all levels Examples how culture is hard-wired throughout STADA Examples how culture is soft-wired throughout STADA STADA+ Performance #CaringForYou STADA Expo management Growth mindset vehicle for S
Slide 89: Management team with strong success track record
Governance & ESG Growth Culture STADA’s management team has a strong success track record across all segments Name & Position Experience Sector expertise Consumer Healthcare Generics Specialty Peter Goldschmidt 1 Chief Executive Officer ✓ ✓ ✓ Boris Döbler Chief Financial Officer ✓ ✓ ✓ Simone Berger
Slide 90: On track to achieve ambitious ESG targets
Governance & ESG ESG STADA is on track to achieve ambitious ESG targets 2024: 65% 2024: 0.35 >65% <0.30 renewable electricity by 2025 Lost Time Incident Rate (LTIR) by 2025 2024: -34% 2024: 80% 42% >90% reduction of GHG emissions by 2030 of spend (direct category) covered by (compared to 2020) EcoVa
Slide 91: ESG rating highlights
Governance & ESG ESG STADA is ranked in the 3rd percentile within Pharmaceuticals ESG rating highlights 18.1 Sustainalytics ESG risk rating score (Low risk)1 Strong ESG risk management (61.2) #3rd percentile within Pharmaceuticals (9th out of 418 companies2 Source: Sustainalytics Note: (1) In 2023,
Slide 92: Appendix: Financials
STADA Appendix Financials
Slide 93: Broad geographic footprint with most countries growing strongly
Financial Appendix Revenues geography Broad geographic footprint with vast majority of countries growing strongly Revenues by country (€m) – 20241,2 Comments % of Group Revenues CAGR 2021 – 2024 0 50 100 150 200 250 300 350 400 800 • Long list of countries with scale Germany 19% 15.2% and strong gro
Slide 94: Diversified portfolio with no product larger than 4% of Revenues
Financial Appendix Revenues by product Diversified portfolio with no product larger than 4% of Group Revenues Revenues by product – 20241,2 Comments % of Group Revenues • CHC with over 1,000 products Nizoral® 2.0% (in the sense of brand or API- Consumer Zoflora® 1.5% name), thereof 241 brands with T
Slide 95: Key foreign currencies and assumptions behind guidance for 2025
Financial Appendix Currencies Key foreign currencies and assumptions behind guidance for 2025 – STADA with relatively limited FX-exposure Revenue in 2024 by currency (% of total) All other 19% • Over 60% of Revenues from entities with EURO as functional currency CHF 5% 7% • Other currencies making l
Slide 96: Adjusted P&L 2024
Financial Appendix 2024 P&L Adjusted P&L 2024: Accretive EBITDA growth in 2024 driven by operating leverage as well as strong expansion of the Specialty business in €m 2023 2024 Growth • Strong topline-growth of +9% with in-market- Revenues 3,735 4,059 +9% outperformance in all three segments Cost o
Slide 97: Gross Profit Adjustments: Mainly PPA effects
Financial Appendix Gross Profit 4Y Gross Profit Adjustments: Mainly PPA effects (in €m) 2021 2022 2023 2024 1⚫ Relates to the elimination of subsequent measurement effects of fair value step- ups included in the consolidated income statement of items initially recognized in Gross Profit 1,177 1,419
Slide 98: EBITDA adjustments
Financial Appendix EBITDA adjustments 4Y EBITDA adjustments: Minor adjustments to ensure better view of underlying performance (in €m) 2021 2022 2023 2024 1⚫ EBITDA adjustments for Purchase Price allocation effects mainly related to EBITDA 577 677 724 840 valuation-effects on the Earn-Out component
Slide 99: IFRS P&L
Financial Appendix IFRS P&L P4Y IFRS P&L Consolidated income statement (€m) 2021 2022 2023 2024 • Over-proportionate operating Revenues 2,852 3,298 3,735 4,059 profit growth based on operating Cost of sales 1,675 1,879 2,119 2,321 leverage (moderate growth in Gross profit 1,177 1,419 1,616 1,738 exp
Slide 100: IFRS Balance Sheet
Financial Appendix IFRS B/S P4Y IFRS Balance Sheet Consolidated balance sheet - Assets (€m) Assets 2021 2022 2023 2024 • Inventory increase in 2023 due Non-current assets 5,551 5,234 4,471 4,532 to deliberate investment to Intangible assets 4,862 4,500 3,686 3,584 secure supply reliability, in 2024
Slide 101: IFRS Balance Sheet (cont'd)
Financial Appendix IFRS B/S P4Y IFRS Balance Sheet (cont’d) Consolidated balance sheet - Equity & Liabilities (€m) Equity & Liabilities 2021 2022 2023 2024 • Other non-current provisions Equity (215) (330) (1,142) (1,318) mainly includes the non-current Subscribed capital 0 0 0 0 portion of the prov
Slide 102: IFRS Cash Flow Statement
Financial Appendix IFRS CFS P4Y IFRS Cash Flow Statement Consolidated Cash Flow statement (€m) 2021 2022 2023 2024 • Operating Cash Flow Result from continuing operations (244) (169) (124) (125) generation based on strong Depreciation, amortization and impairments net of reversals of impairments of
Slide 103: IFRS Cash Flow Statement (cont'd)
Financial Appendix IFRS CFS P4Y IFRS Cash Flow Statement (cont’d) Consolidated Cash Flow statement (€m) 2021 2022 2023 2024 Payments for investments in: intangible assets (233) (163) (163) (130) • Investments in intangible property, plant and equipment (69) (58) (97) (80) assets in 2021 and 2023 inc
STADA Arzneimittel — Investor Presentation (July 2025) on 6ix